Do analysts prefer BDRX or ALLR?

Allarity Therapeutics has a consensus price target of $10.25, indicating a potential upside of 790.53%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Allarity Therapeutics is more favorable than Biodexa Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, BDRX or ALLR?

Biodexa Pharmaceuticals has higher earnings, but lower revenue than Allarity Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodexa Pharmaceuticals N/A N/A -$8.42M N/A N/A Allarity Therapeutics $345K 53.08 -$11.23M -$0.72 N/A

Is BDRX or ALLR more profitable?

Biodexa Pharmaceuticals' return on equity of 0.00% beat Allarity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Biodexa Pharmaceuticals N/A N/A N/A Allarity Therapeutics N/A -109.94% -47.27%

Do analysts recommend PLUR or BDRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, PLUR or BDRX?

Biodexa Pharmaceuticals has lower revenue, but higher earnings than Pluri. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pluri $1.08M 17.70 -$22.58M -$4.53 N/A Biodexa Pharmaceuticals N/A N/A -$8.42M N/A N/A

Is PLUR or BDRX more profitable?

Biodexa Pharmaceuticals has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Company Net Margins Return on Equity Return on Assets Pluri -2,162.08% N/A -106.59% Biodexa Pharmaceuticals N/A N/A N/A

Do analysts recommend BDRX or GTBP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, BDRX or GTBP?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodexa Pharmaceuticals N/A N/A -$8.42M N/A N/A GT Biopharma N/A N/A -$28.35M -$6.33 N/A

Is BDRX or GTBP more profitable?

Company Net Margins Return on Equity Return on Assets Biodexa Pharmaceuticals N/A N/A N/A GT Biopharma N/A N/A -102.03%

Do analysts recommend BDRX or JSPR?

Jasper Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 1,530.43%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than Biodexa Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Jasper Therapeutics 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38

Which has better valuation and earnings, BDRX or JSPR?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodexa Pharmaceuticals N/A N/A -$8.42M N/A N/A Jasper Therapeutics N/A N/A -$75.80M -$3.23 N/A

Is BDRX or JSPR more profitable?

Biodexa Pharmaceuticals' return on equity of 0.00% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Biodexa Pharmaceuticals N/A N/A N/A Jasper Therapeutics N/A -613.51% -162.52%

Do analysts prefer BDRX or QNCX?

Quince Therapeutics has a consensus price target of $690.00, suggesting a potential upside of 3,243.19%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Quince Therapeutics is more favorable than Biodexa Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quince Therapeutics 2 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.20

Which has higher valuation & earnings, BDRX or QNCX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodexa Pharmaceuticals N/A N/A -$8.42M N/A N/A Quince Therapeutics N/A N/A -$83.98M -$212.40 N/A

Is BDRX or QNCX more profitable?

Company Net Margins Return on Equity Return on Assets Biodexa Pharmaceuticals N/A N/A N/A Quince Therapeutics N/A N/A -67.99%

Biodexa Pharmaceuticals (BDRX) Competitors

$2.24 +0.01 (+0.22%)

As of 01:46 PM Eastern

Compare

BDRX vs. ALLR, PLUR, GTBP, JSPR, and QNCX

Should you buy Biodexa Pharmaceuticals stock or one of its competitors? MarketBeat compares Biodexa Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biodexa Pharmaceuticals include Allarity Therapeutics (ALLR), Pluri (PLUR), GT Biopharma (GTBP), Jasper Therapeutics (JSPR), and Quince Therapeutics (QNCX). These companies are all part of the "pharmaceutical products" industry.

How does Biodexa Pharmaceuticals compare to Allarity Therapeutics?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of Allarity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Biodexa Pharmaceuticals and Biodexa Pharmaceuticals both had 2 articles in the media. Allarity Therapeutics' average media sentiment score of 0.96 beat Biodexa Pharmaceuticals' score of 0.43 indicating that Allarity Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Biodexa Pharmaceuticals	Neutral
Allarity Therapeutics	Positive

Biodexa Pharmaceuticals has higher earnings, but lower revenue than Allarity Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	N/A	N/A	-$8.42M	N/A	N/A
Allarity Therapeutics	$345K	53.08	-$11.23M	-$0.72	N/A

Allarity Therapeutics has a consensus price target of $10.25, indicating a potential upside of 790.53%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Allarity Therapeutics is more favorable than Biodexa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Biodexa Pharmaceuticals has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

Biodexa Pharmaceuticals' return on equity of 0.00% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
Allarity Therapeutics	N/A	-109.94%	-47.27%

Summary

Biodexa Pharmaceuticals beats Allarity Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to Pluri?

Pluri (NASDAQ:PLUR) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

In the previous week, Pluri had 1 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 3 mentions for Pluri and 2 mentions for Biodexa Pharmaceuticals. Pluri's average media sentiment score of 0.62 beat Biodexa Pharmaceuticals' score of 0.43 indicating that Pluri is being referred to more favorably in the media.

Company	Overall Sentiment
Pluri	Positive
Biodexa Pharmaceuticals	Neutral

Biodexa Pharmaceuticals has lower revenue, but higher earnings than Pluri.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.08M	17.70	-$22.58M	-$4.53	N/A
Biodexa Pharmaceuticals	N/A	N/A	-$8.42M	N/A	N/A

Pluri has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, Biodexa Pharmaceuticals has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

16.6% of Pluri shares are owned by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. 43.2% of Pluri shares are owned by insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Biodexa Pharmaceuticals has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,162.08%	N/A	-106.59%
Biodexa Pharmaceuticals	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Biodexa Pharmaceuticals beats Pluri on 5 of the 9 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to GT Biopharma?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and GT Biopharma (NASDAQ:GTBP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Biodexa Pharmaceuticals has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
GT Biopharma	N/A	N/A	-102.03%

In the previous week, Biodexa Pharmaceuticals had 1 more articles in the media than GT Biopharma. MarketBeat recorded 2 mentions for Biodexa Pharmaceuticals and 1 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 1.91 beat Biodexa Pharmaceuticals' score of 0.43 indicating that GT Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Biodexa Pharmaceuticals	Neutral
GT Biopharma	Very Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	N/A	N/A	-$8.42M	N/A	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A

17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.2% of GT Biopharma shares are owned by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are owned by insiders. Comparatively, 1.2% of GT Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Biodexa Pharmaceuticals beats GT Biopharma on 5 of the 7 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to Jasper Therapeutics?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

Biodexa Pharmaceuticals has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.07, suggesting that its stock price is 207% more volatile than the broader market.

In the previous week, Biodexa Pharmaceuticals had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 2 mentions for Biodexa Pharmaceuticals and 1 mentions for Jasper Therapeutics. Biodexa Pharmaceuticals' average media sentiment score of 0.43 beat Jasper Therapeutics' score of 0.35 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Biodexa Pharmaceuticals	Neutral
Jasper Therapeutics	Neutral

Biodexa Pharmaceuticals' return on equity of 0.00% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
Jasper Therapeutics	N/A	-613.51%	-162.52%

Jasper Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 1,530.43%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than Biodexa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. Comparatively, 79.8% of Jasper Therapeutics shares are held by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are held by insiders. Comparatively, 2.3% of Jasper Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	N/A	N/A	-$8.42M	N/A	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A

Summary

Jasper Therapeutics beats Biodexa Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to Quince Therapeutics?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

Biodexa Pharmaceuticals has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are held by insiders. Comparatively, 7.1% of Quince Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	N/A	N/A	-$8.42M	N/A	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$212.40	N/A

In the previous week, Biodexa Pharmaceuticals and Biodexa Pharmaceuticals both had 2 articles in the media. Quince Therapeutics' average media sentiment score of 1.44 beat Biodexa Pharmaceuticals' score of 0.43 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Biodexa Pharmaceuticals	Neutral
Quince Therapeutics	Positive

Quince Therapeutics has a consensus price target of $690.00, suggesting a potential upside of 3,243.19%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Quince Therapeutics is more favorable than Biodexa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.20

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
Quince Therapeutics	N/A	N/A	-67.99%

Summary

Quince Therapeutics beats Biodexa Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

Get Biodexa Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BDRX vs. The Competition

Export

Metric	Biodexa Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.49M	$3.68B	$6.87B	$12.58B
Dividend Yield	N/A	2.22%	2.68%	9.45%
P/E Ratio	N/A	21.36	27.21	24.30
Price / Sales	N/A	177.62	516.66	87.93
Price / Cash	N/A	143.89	48.63	60.00
Price / Book	0.02	8.47	10.81	6.27
Net Income	-$8.42M	$23.88M	$3.59B	$331.55M
7 Day Performance	-13.24%	-4.59%	-2.12%	-1.53%
1 Month Performance	-24.60%	5.93%	3.24%	-0.59%
1 Year Performance	-94.65%	46.68%	26.02%	18.83%

Biodexa Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BDRX Biodexa Pharmaceuticals	0.3217 of 5 stars	$2.25 +0.2%	N/A	-94.9%	$4.48M	N/A	N/A	20
ALLR Allarity Therapeutics	2.3351 of 5 stars	$1.16 +2.7%	$10.25 +783.6%	+16.8%	$17.98M	$320K	N/A	10	Short Interest Decrease
PLUR Pluri	0.8261 of 5 stars	$1.68 +3.1%	N/A	-65.1%	$17.59M	$1.34M	N/A	150	High Trading Volume
GTBP GT Biopharma	0.6177 of 5 stars	$0.37 -4.8%	N/A	-82.5%	$17.19M	N/A	N/A	8	Positive News
JSPR Jasper Therapeutics	3.03 of 5 stars	$0.72 +18.9%	$12.00 +1,560.2%	-79.1%	$17.02M	N/A	N/A	20	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BDRX) was last updated on 7/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biodexa Pharmaceuticals (BDRX) Competitors

BDRX vs. ALLR, PLUR, GTBP, JSPR, and QNCX

How does Biodexa Pharmaceuticals compare to Allarity Therapeutics?

Summary

How does Biodexa Pharmaceuticals compare to Pluri?

Summary

How does Biodexa Pharmaceuticals compare to GT Biopharma?

Summary

How does Biodexa Pharmaceuticals compare to Jasper Therapeutics?

Summary

How does Biodexa Pharmaceuticals compare to Quince Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX vs. The Competition

Biodexa Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biodexa Pharmaceuticals (BDRX) Competitors

BDRX vs. ALLR, PLUR, GTBP, JSPR, and QNCX

How does Biodexa Pharmaceuticals compare to Allarity Therapeutics?

Do institutionals and insiders have more ownership in BDRX or ALLR?

Does the media favor BDRX or ALLR?

Which has preferable earnings & valuation, BDRX or ALLR?

Do analysts prefer BDRX or ALLR?

Which has more volatility and risk, BDRX or ALLR?

Is BDRX or ALLR more profitable?

Summary

How does Biodexa Pharmaceuticals compare to Pluri?

Does the media prefer PLUR or BDRX?

Which has better earnings and valuation, PLUR or BDRX?

Which has more volatility and risk, PLUR or BDRX?

Do insiders & institutionals believe in PLUR or BDRX?

Is PLUR or BDRX more profitable?

Do analysts recommend PLUR or BDRX?

Summary

How does Biodexa Pharmaceuticals compare to GT Biopharma?

Which has more risk & volatility, BDRX or GTBP?

Is BDRX or GTBP more profitable?

Does the media prefer BDRX or GTBP?

Which has better earnings & valuation, BDRX or GTBP?

Do insiders and institutionals hold more shares of BDRX or GTBP?

Do analysts recommend BDRX or GTBP?

Summary

How does Biodexa Pharmaceuticals compare to Jasper Therapeutics?

Which has more volatility & risk, BDRX or JSPR?

Does the media favor BDRX or JSPR?

Is BDRX or JSPR more profitable?

Do analysts recommend BDRX or JSPR?

Do insiders and institutionals hold more shares of BDRX or JSPR?

Which has better valuation and earnings, BDRX or JSPR?

Summary

How does Biodexa Pharmaceuticals compare to Quince Therapeutics?

Which has more volatility & risk, BDRX or QNCX?

Do institutionals & insiders have more ownership in BDRX or QNCX?

Which has higher valuation & earnings, BDRX or QNCX?

Does the media favor BDRX or QNCX?

Do analysts prefer BDRX or QNCX?

Is BDRX or QNCX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX vs. The Competition

Biodexa Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools